Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors

Affiliations

• ¹ Department of Dermatology, Stanford University School of Medicine, Palo Alto, California.
• ² Department of BioPhysics, Stanford University School of Medicine, Palo Alto, California.
• ³ Department of Dermatology, Stanford University School of Medicine, Palo Alto, California; Department of Pathology, Stanford University School of Medicine, Stanford, California.
• ⁴ Division of Immunology & Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California; VA Palo Alto Health Care System, Palo Alto, California.
• ⁵ Department of Dermatology, Stanford University School of Medicine, Palo Alto, California. Electronic address: lisa.zaba@stanford.edu.